Poland· PL-100513757

Nemluvio

A nemolizumab product containing nemolizumab, registered in Poland by Galderma International. The same ATC class is registered in 14 of our 19 countries.

ATC D11AH12

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedNemluvioATCD11AH12REGISTER NO.PL-100513757PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Nemolizumab is registered in 14 of 19 countries.

Countries holding a registration under ATC D11AH12 (nemolizumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Nemolizumab · ATC D11AH12

14 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of nemolizumab costs, country by country.

Normalised to the WHO defined daily dose (0.8 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Nemolizumab · price per daily dose (0.8 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$67.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Nemolizumab
Manufacturer
Galderma International
Country
Poland (PL)
ATC code
D11AH12
ATC class
Nemolizumab
Defined daily dose
0.8 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ead22350-ce7d-4aa1-9d77-de5000a52623
GET /v1/drugs/ead22350-ce7d-4aa1-9d77-de5000a52623?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań w ampułko-strzykawce",
  "source": "urpl",
  "strength": "30 mg",
  "packaging": "Rpz ¦ EU/1/24/1901/004 ¦ 160577\n1 amp.-strzyk. 0,49 ml ¦ 1 igła  z osłoną zabezpieczającą",
  "substance": "Nemolizumab 30 mg",
  "common_name": "Nemolizumab",
  "pl_product_id": "100513757",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}

See everything about nemolizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.